Lyell Immunopharma/$LYEL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lyell Immunopharma
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
Ticker
$LYEL
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
300
ISIN
US55083R2031
Website
LYEL Metrics
BasicAdvanced
$145M
-
-$24.63
-0.27
-
Price and volume
Market cap
$145M
Beta
-0.27
52-week high
$13.80
52-week low
$7.65
Financial strength
Current ratio
7.489
Quick ratio
7.295
Long term debt to equity
14.516
Total debt to equity
16.964
Profitability
EBITDA (TTM)
-201.401
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-514,649.23%
Operating margin (TTM)
-337,613.85%
Management effectiveness
Return on assets (TTM)
-24.40%
Return on equity (TTM)
-71.20%
Valuation
Price to revenue (TTM)
2,042.224
Price to book
0.43
Price to tangible book (TTM)
0.43
Price to free cash flow (TTM)
-0.755
Free cash flow yield (TTM)
-132.46%
Free cash flow per share (TTM)
-1,294.09%
Growth
Revenue change (TTM)
-4.41%
Earnings per share change (TTM)
35.96%
3-year revenue growth (CAGR)
-80.49%
3-year earnings per share growth (CAGR)
-3.42%
LYEL News
AllArticlesVideos
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series
GlobeNewsWire·3 weeks ago
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
GlobeNewsWire·3 weeks ago
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lyell Immunopharma stock?
Lyell Immunopharma (LYEL) has a market cap of $145M as of July 11, 2025.
What is the P/E ratio for Lyell Immunopharma stock?
The price to earnings (P/E) ratio for Lyell Immunopharma (LYEL) stock is 0 as of July 11, 2025.
Does Lyell Immunopharma stock pay dividends?
No, Lyell Immunopharma (LYEL) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Lyell Immunopharma dividend payment date?
Lyell Immunopharma (LYEL) stock does not pay dividends to its shareholders.
What is the beta indicator for Lyell Immunopharma?
Lyell Immunopharma (LYEL) has a beta rating of -0.27. This means that it has an inverse relation to market volatility.